D015941PhenomenaProceduresE01.370.225.812.160.155E01.370.225.812.735.155E05.200.812.160.155E05.200.812.735.155E05.478.594.160.150E05.478.594.760.155Complement Hemolytic Activity Assayprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfConnectionsnumber of connectionsprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierInformation Resourcevivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConcept0.1272380.03313412subject area for7527236Saifuddin M, Ghassemi M, Patki C, Parker CJ, Spear GTAIDS research and human retrovirusesHost cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res Hum Retroviruses. 1994 Jul; 10(7):829-37.AIDS Res Hum Retroviruses1994-07-01T00:00:001994Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis.7851010Saarloos MN, Lint TF, Spear GTClinical and experimental immunologyEfficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells. Clin Exp Immunol. 1995 Feb; 99(2):189-95.Clin Exp Immunol1995-02-01T00:00:001995Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells.